[go: up one dir, main page]

WO2007038579A1 - L'expression du bas permettant de prevoir la reponse au traitement d'une maladie hematologique - Google Patents

L'expression du bas permettant de prevoir la reponse au traitement d'une maladie hematologique Download PDF

Info

Publication number
WO2007038579A1
WO2007038579A1 PCT/US2006/037647 US2006037647W WO2007038579A1 WO 2007038579 A1 WO2007038579 A1 WO 2007038579A1 US 2006037647 W US2006037647 W US 2006037647W WO 2007038579 A1 WO2007038579 A1 WO 2007038579A1
Authority
WO
WIPO (PCT)
Prior art keywords
bax
levels
drug
sample
hematologic disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/037647
Other languages
English (en)
Inventor
William Stratford May
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
University of Florida Research Foundation Inc
Original Assignee
University of Florida
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida
Publication of WO2007038579A1 publication Critical patent/WO2007038579A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • Bax protein is essential for initiating cell death (Cao et al, Cleavage of Bax to pi 8 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade pl8 Bax. Blood. 2003 Oct 1; 102(7): 2605-14). Following chemotherapy- induced stress, cytosolic Bax fully integrates into the outer mitochondrial membrane where it oligomerizes and forms death pores that facilitate the release of cytochrome c and other pro-apoptotic activators (Wood et al, Cleavage of Bax enhances its cell death function. Exp Cell Res.
  • Bax is cleaved by calpain at aspartate 33 (Asp33) to yield pi 8 Bax during stress- induced apoptosis.
  • An ecdysone-inducible expression system has been used to assess the role of pi 8 Bax in apoptosis.
  • Similar levels of wild-type (WT) and noncleavable Asp33Ala (Asp ⁇ >Ala) Bax are induced in 293 cells while expression of N-terminal- deleted pl8 (Deltal-33) Bax remains low (20% of full-length p21 Bax) due to a reduced half-life (2 hours versus 12 hours for p21 Bax) resulting from increased sensitivity to cathepsin-like proteolytic degradation.
  • pi 8 Bax is enhanced to levels comparable to p21 Bax when induction is carried out in the presence of cathepsin inhibitors, Z-Phe-Gly-NHO-Bz or N-Acetyl-Leu-Leu-Met-CHO.
  • p21 Bax WT Bax
  • As ⁇ 33Ala Bax more potently induces apoptosis as indicated by increased cytochrome c release, caspase- 91-3 activation, and DNA fragmentation, potentially due to their increased homo- oligomerization in mitochondrial membranes.
  • One embodiment of the invention provides a method of determining response of a patient with a hematologic disease to a drug.
  • the method comprises contacting a blood sample or a bone marrow sample from the patient with the drug and analyzing the sample for levels of p21 Bax or pi 8 Bax or both p21 and pi 8 Bax.
  • An increase in levels of p21 Bax or pi 8 Bax or both p21 Bax and pi 8 Bax as compared to the levels prior to treatment or to a control level indicates a positive response of the patient to the drug.
  • the levels of p21 Bax and pl8 Bax can be determined using antibodies specific for pi 8 Bax, antibodies specific for p21 Bax, antibodies specific for pi 8 Bax and p21 Bax, or combinations thereof.
  • the hematologic disease can be acute myelogenous leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, extramedullary plasmacytoma, solitary myeloma, indolent myeloma, myelodysplastic syndrome, a myeloproliferative disorder, polycythemia vera, essential thrombocythemia, or idiopathic myelofibrosis.
  • the drug can be daunorubicin, ATRA (all-trans retinoic acid), chlorambucil, cyclophosphamide, melphalan, doxorubicin, idarubicin, mitoxantrone, imethotrexate, fludarabine, cytarabine, etoposide, topotecan, prednisone, dexamethasone, vincristine, vinblastine or combinations thereof.
  • ATRA all-trans retinoic acid
  • chlorambucil cyclophosphamide
  • melphalan doxorubicin
  • idarubicin mitoxantrone
  • imethotrexate fludarabine
  • cytarabine etoposide
  • topotecan prednisone
  • dexamethasone vincristine, vinblastine or combinations thereof.
  • Another embodiment of the invention provides a method of determining the response of a patient with a hematologic disease to treatment.
  • the method comprises obtaining a blood sample or a bone marrow sample from the patient and analyzing the sample for levels of pi 8 Bax.
  • An increase in levels of pi 8 Bax as compared to a control sample indicates a positive response of the patient to treatment.
  • Yet another embodiment of the invention provides a method of determining if a drug is effective against a hematologic disease.
  • the method comprises contacting a blood sample or a bone marrow sample from a hematologic disease patient with the drug and analyzing the sample for levels of p21 Bax or pi 8 Bax or both p21 and pi 8 Bax.
  • An increase in levels of p21 Bax or pi 8 Bax or both p21 Bax and pi 8 Bax indicates the drug is effective against a hematologic disease.
  • FIG. 1 Spectrin degradation in leukemia cells exposed to chemotherapy.
  • Lane 1 represents control lane.
  • Lane 2 contains cell lysate proteins from cells exposed to just cytarabine pre-treatment.
  • Lane 3 contains cell lysate proteins from cells exposed to just daunorubicin pre-treatment.
  • Lane 4 contains cell lysate proteins from cells exposed to both cytarabine and daunorubicin.
  • Spectrin degradation as a result of apoptosis is detected using antibodies directed against degradation products. This sample is from UPN 5 showing marked increased apoptosis when cells are exposed to daunorubicin.
  • FIG. 1 Bax expression in leukemia cells exposed to chemotherapy.
  • Lane 1 represents control lane.
  • Lane 2 contains cell lysate proteins from cells exposed to just cytarabine pre-treatment.
  • Lane 3 contains cell lysate proteins from cells exposed to just daunorubicin pre-treatment.
  • Lane 4 contains cell lysate proteins from cells exposed to both cytarabine and daunorubicin. This sample is from UPN 5.
  • Cell lysates after exposure to daunorubicin (lanes 3 and 4) demonstrate increased truncated Bax (pi 8).
  • Apoptosis via the intrinsic cell death pathway is characterized by mitochondrial dysfunction followed by release of caspase activators that destroy cell structure and function
  • Increased levels of pi 8 Bax in cells from patients with hematologic diseases correlates with chemosensitivity and potentially, disease remission. Therefore, detection of pi 8 Bax can be used in prognosis of a patient at the time of diagnosis.
  • a hematologic disease is a cancer of the blood or bone marrow, such as leukemia or lymphoma.
  • hematologic diseases include, for example, acute myelogenous leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, extramedullar plasmacytoma, solitary myeloma, indolent myeloma, myelodysplastic syndrome, and myeloproliferative disorders such as, polycythemia vera, essential (or primary) thrombocythemia, and idiopathic myelofibrosis.
  • Any drugs that can potentially treat a hematologic disease can be used in the methods of the invention, e.g., daunorubicin, ATRA (all-trans retinoic acid), chlorambucil, cyclophosphamide, melphalan, doxorubicin, idarubicin, mitoxantrone, methotrexate, fludarabine, cytarabine, etoposide, topotecan, prednisone and dexamethasone, vincristine and vinblastine.
  • daunorubicin e.g., ATRA (all-trans retinoic acid), chlorambucil, cyclophosphamide, melphalan, doxorubicin, idarubicin, mitoxantrone, methotrexate, fludarabine, cytarabine, etoposide, topotecan, prednisone and dexamethasone, vincristine and
  • Methods of the invention provide assays for determining the response of a patient with a hematologic disease to a drug treatment.
  • a blood sample or a bone marrow sample from the patient can be contacted with the drug.
  • the blood or bone marrow sample is then analyzed for the level of the p21 Bax or pi 8 Bax or both p21 and pi 8 Bax.
  • An increase in levels of p21 Bax or pi 8 Bax or both p21 Bax and pi 8 Bax as compared to the levels prior to the treatment or to control levels indicates a positive response of the patient to the drug.
  • the methods comprise obtaining a blood sample or a bone marrow sample from the patient and analyzing the sample for levels of pi 8 Bax an increase in levels of pi 8 Bax as compared to a control sample indicates a positive response of the patient to treatment.
  • the invention also provides methods of determining if a drug is effective against a hematologic disease.
  • a blood sample or a bone marrow sample from a hematologic disease patient is contacted with one or more drugs.
  • the blood or bone marrow samples are analyzed for levels of p21 Bax or pi 8 Bax or both p21 and pl8Bax.
  • An increase in levels of p21 Bax or pi 8 Bax or both p21 Bax and pi 8 Bax indicates the drug is effective against a hematologic disease.
  • Blood samples can include, e.g., plasma, serum, whole blood or peripheral blood mononuclear cells.
  • An antibody, aptamer, or nanoparticle can be used to detect p21 Bax and/or pi 8 Bax.
  • an antibody that binds to both pi 8 and to p21 Bax can be used. The two forms can then be differentiated by size analysis.
  • An antibody can be used that binds both pi 8 and p21 Bax along with an antibody that binds to one or more of the 33 N- terminal amino acids of p21 Bax (this antibody would not bind to pi 8 Bax since pi 8 Bax does not have the 33 N-terminal amino acids of p21 Bax).
  • an antibody that binds p21 Bax exclusively and one that binds pi 8 Bax exclusively can be used.
  • Antibodies to Bax are commercially available from, e.g., Santa Cruz Biotechnology, Inc, Santa Cruz, CA; Abeam, Cambridge, MA; Accurate Chemical, Westbury, NY; Axxora, San Diego, CA; Sigma Aldrich; Biodesign International, Saco, Maine; Biogenesis, Kinston NH; Biogenex, San Romon, CA; Southern Biotechnology Assoc, Birmingham AL, Bionostics, Devens, MA; Biosource, Camarillo, CA; Trevigen, Gaithersburg, MD.
  • Antibodies of the invention are antibody molecules that specifically and stably bind to pi 8 Bax or p21 Bax or both.
  • An antibody of the invention can be a polyclonal antibody, a monoclonal antibody, a single chain antibody (scFv), or a fragment of an antibody. Fragments of antibodies are a portion of an intact antibody comprising the antigen binding site or variable region of an intact antibody, wherein the portion is free of the constant heavy chain domains of the Fc region of the intact antibody. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab') 2 and F v fragments.
  • An antibody of the invention can be any antibody class, including for example, IgG, IgM, IgA, IgD and IgE.
  • An antibody or fragment thereof binds to an epitope of a polypeptide of the invention.
  • An antibody can be made in vivo in suitable laboratory animals or in vitro using recombinant DNA techniques. Means for preparing and characterizing antibodies are well know in the art. See, e.g., Dean, Methods MoI. Biol. 80:23-37 (1998); Dean, Methods MoI. Biol. 32:361-79 (1994); Baileg, Methods MoI. Biol. 32:381-88 (1994); Gullick, Methods MoI.
  • polyclonal antibodies can be produced by administering p 18 Bax, p21 Bax, or a fragment thereof to an animal, such as a human or other primate, mouse, rat, rabbit, guinea pig, goat, pig, dog, cow, sheep, donkey, or horse.
  • an animal such as a human or other primate, mouse, rat, rabbit, guinea pig, goat, pig, dog, cow, sheep, donkey, or horse.
  • Serum from the immunized animal is collected and the antibodies are purified from the plasma by, for example, precipitation with ammonium sulfate, followed by chromatography, such as affinity chromatography.
  • chromatography such as affinity chromatography.
  • Specifically binds or “specific for” means that the polypeptide recognizes and binds to an antibody of the invention with greater affinity than to other, non-specific molecules.
  • an antibody raised against an antigen e.g., a polypeptide
  • RIA radioimmunoassay
  • a western blot assay using methodology well known in the art.
  • monoclonal antibodies directed against epitopes present on pi 8 Bax or p21 Bax can also be readily produced.
  • normal B cells from a mammal, such as a mouse which was immunized with a Bax polypeptide can be fused with, for example, HAT-sensitive mouse myeloma cells to produce hybridomas.
  • Hybridomas producing Bax-specific antibodies can be identified using RIA or ELISA and isolated by cloning in semi-solid agar or by limiting dilution. Clones producing Bax-specific antibodies are isolated by another round of screening.
  • Monoclonal antibodies can be screened for specificity using standard techniques, for example, by binding a Bax polypeptide to a microtiter plate and measuring binding of the monoclonal antibody by an ELISA assay.
  • Techniques for producing and processing monoclonal antibodies are known in the art. See e.g., Kohler & Milstein, Nature, 256:495 (1975).
  • Particular isotypes of a monoclonal antibody can be prepared directly, by selecting from the initial fusion, or prepared secondarily, from a parental hybridoma secreting a monoclonal antibody of a different isotype by using a sib selection technique to isolate class-switch variants. See Steplewski et al, P.N.A.S.
  • Monoclonal antibodies of the invention can also be recombinant monoclonal antibodies. See, e.g., U.S. Patent No. 4,474,893; U.S. Patent No. 4,816,567.
  • Antibodies of the invention can also be chemically constructed. See, e.g., U.S. Patent No. 4,676,980.
  • Antibodies of the invention can be chimeric ⁇ see, e.g., U.S. Patent No. 5,482,856), humanized ⁇ see, e.g., Jones et al, Nature 321:522 (1986); Reichmann et al., Nature 332:323 (1988); Presta, Curr. Op. Struct. Biol. 2:593 (1992)), or human antibodies.
  • Human antibodies can be made by, for example, direct immortilization, phage display, transgenic mice, or a Trimera methodology, see e.g., Reisener et al, Trends Biotechnol. 16:242-246 (1998).
  • Antibodies that specifically bind Bax antigens are particularly useful for detecting the presence of Bax in a sample, such as a serum, blood, or bone marrow sample from an animal such as a human.
  • An immunoassay for Bax can utilize one antibody or several antibodies.
  • An immunoassay for Bax can use, for example, a monoclonal antibody directed towards a Bax epitope, a combination of monoclonal antibodies directed towards epitopes of one Bax polypeptide, monoclonal antibodies directed towards epitopes of different Bax polypeptides, polyclonal antibodies directed towards the same Bax antigen, polyclonal antibodies directed towards different Bax antigens, or a combination of monoclonal and polyclonal antibodies.
  • Immunoassay protocols can be based upon, for example, competition, direct reaction, or sandwich type assays using, for example, labeled antibody.
  • Antibodies of the invention can be labeled with any type of label known in the art, including, for example, fluorescent, chemiluminescent, radioactive, enzyme, colloidal metal, radioisotope and bioluminescent labels.
  • Antibodies of the invention or fragments thereof can be bound to a support and used to detect the presence of Bax.
  • Supports include, for example, glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amylases, natural and modified celluloses, polyacrylamides, agaroses and magletite.
  • Antibodies of the invention can further be used to isolate Bax by immunoaffmity columns.
  • the antibodies can be affixed to a solid support by, for example, adsorbtion or by covalent linkage so that the antibodies retain their immunoselective activity.
  • spacer groups can be included so that the antigen binding site of the antibody remains accessible.
  • the immobilized antibodies can then be used to bind Bax antigens from a sample, such as a biological sample including, e.g., blood or bone marrow.
  • the bound Bax is recovered from the column matrix by, for example, a change in pH.
  • the methods of the invention can be used to detect pi 8 Bax and/or p21 Bax in a test sample, such as blood or bone marrow.
  • the test sample can be untreated, precipitated, fractionated, separated, diluted, concentrated, or purified.
  • the methods can comprise contacting antibodies specific for pi 8 Bax and/or p21 Bax with a test sample under conditions that allow a polypeptide/antibody complex, i.e., an immunocomplex, to form. That is, antibodies bind to pi 8 Bax and/or p21 Bax located in the sample.
  • a polypeptide/antibody complex i.e., an immunocomplex
  • One of skill in the art is familiar with assays and conditions that are used to detect antibody/polypeptide complex binding. The formation of a complex between Bax and antibodies in the sample is detected. The amount of antibody-antigen complexes can be determined by methodology known in the art.
  • the polypeptide/antibody complex is detected when an indicator reagent, such as an enzyme conjugate, which is bound to the antibody, catalyzes a detectable reaction.
  • an indicator reagent comprising a signal generating compound can be applied to the polypeptide/antibody complex under conditions that allow formation of a polypeptide/antibody/indicator complex.
  • the polypeptide/antibody/indicator complex is detected.
  • the polypeptide or antibody can be labeled with an indicator reagent prior to the formation of a polypeptide/antibody complex.
  • the method can optionally comprise a positive or negative control.
  • antibodies specific for Bax are attached to a solid phase or substrate.
  • a test sample potentially comprising Bax is added to the substrate.
  • Antibodies that specifically bind pi 8 Bax and/or p21 Bax are added.
  • the antibodies can be the same antibodies used on the solid phase or can be from a different source or species and can be linked to an indicator reagent, such as an enzyme conjugate. Wash steps can be performed prior to each addition.
  • a chromophore or enzyme substrate is added and color is allowed to develop. The color reaction is stopped and the color can be quantified using, for example, a spectrophotometer.
  • Assays of the invention include, but are not limited to those based on competition, direct reaction or sandwich-type assays, including, but not limited to enzyme linked immunosorbent assay (ELISA), western blot, IFA, radioimmunoassay (RIA), hemagglutination (HA), fluorescence polarization immunoassay (FPIA), and microtiter plate assays (any assay done in one or more wells of a microtiter plate).
  • ELISA enzyme linked immunosorbent assay
  • RIA radioimmunoassay
  • HA hemagglutination
  • FPIA fluorescence polarization immunoassay
  • microtiter plate assays any assay done in one or more wells of a microtiter plate.
  • Assays can use solid phases or substrates or can be performed by immunoprecipitation or any other methods that do not utilize solid phases.
  • a solid phase or substrate an antibody is directly or indirectly attached to a solid support or a substrate such as a microtiter well, magnetic bead, non-magnetic bead, column, matrix, membrane, fibrous mat composed of synthetic or natural fibers (e.g., glass or cellulose-based materials or thermoplastic polymers, such as, polyethylene, polypropylene, or polyester), sintered structure composed of particulate materials (e.g., glass or various thermoplastic polymers), or cast membrane film composed of nitrocellulose, nylon, polysulfone or the like (generally synthetic in nature).
  • synthetic or natural fibers e.g., glass or cellulose-based materials or thermoplastic polymers, such as, polyethylene, polypropylene, or polyester
  • sintered structure composed of particulate materials
  • particulate materials e.g., glass or various thermoplastic polymers
  • cast membrane film composed of
  • substrate materials can be used in suitable shapes, such as films, sheets, or plates, or they may be coated onto or bonded or laminated to appropriate inert carriers, such as paper, glass, plastic films, or fabrics.
  • suitable methods for immobilizing antibodies on solid phases include ionic, hydrophobic, covalent interactions and the like.
  • polypeptide/antibody complex or a polypeptide/antibody/indicator complex can be detected by radiometric, colormetric, fluorometric, size-separation, or precipitation methods.
  • detection of a polypeptide/antibody complex is by the addition of a secondary antibody that is coupled to an indicator reagent comprising a signal generating compound.
  • Indicator reagents comprising signal generating compounds (labels) associated with a polypeptide/antibody complex can be detected using the methods described above and include chromogenic agents, catalysts such as enzyme conjugates fluorescent compounds such as fluorescein and rhodamine, chemiluminescent compounds such as dioxetanes, acridiniums, phenanthridiniums, ruthenium, and luminol, radioactive elements, direct visual labels, as well as cofactors, inhibitors, magnetic particles, and the like.
  • enzyme conjugates include alkaline phosphatase, horseradish peroxidase, beta-galactosidase, and the like. The selection of a particular label is not critical, but it will be capable of producing a signal either by itself or in conjunction with one or more additional substances.
  • the objectives of this example were to correlate pi 8 Bax in cancer cells with clinical outcome.
  • the strategy of the study was to evaluate circulating blood cells in patients with cancer, in order to provide better prognostic information and identify molecular mechanisms to increase chemotherapy sensitivity.
  • Peripheral blood mononuclear cells from the patients were isolated by Ficoll separation. Cells were then treated with cytarabine, daunorubicin, or a combination of cytarabine and daunorubicin. Cytarabine treated cells were exposed to a 20 micromolar for 24 hours. For daunorubicin treatment, cells were exposed to a concentration of 0.5 micrograms per milliliter for 24 hours. Cells were then lysed. Proteins were analyzed by Western blot. The blots were probed with anti-human spectrin degradation products, Bax (p21), and truncated Bax (pi 8).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des méthodes de détermination de la réponse d'un patient atteint d'une maladie hématologique à un médicament par analyse d'échantillon de sang ou de moelle pour y déceler le Bas p21, le Bas pli, ou les deux.
PCT/US2006/037647 2005-09-26 2006-09-26 L'expression du bas permettant de prevoir la reponse au traitement d'une maladie hematologique Ceased WO2007038579A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72050705P 2005-09-26 2005-09-26
US60/720,507 2005-09-26

Publications (1)

Publication Number Publication Date
WO2007038579A1 true WO2007038579A1 (fr) 2007-04-05

Family

ID=37650635

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/037210 Ceased WO2007038406A1 (fr) 2005-09-26 2006-09-26 Prediction de la reponse d'une maladie hematologique a un traitement par l'expression de bax
PCT/US2006/037647 Ceased WO2007038579A1 (fr) 2005-09-26 2006-09-26 L'expression du bas permettant de prevoir la reponse au traitement d'une maladie hematologique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2006/037210 Ceased WO2007038406A1 (fr) 2005-09-26 2006-09-26 Prediction de la reponse d'une maladie hematologique a un traitement par l'expression de bax

Country Status (1)

Country Link
WO (2) WO2007038406A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840923A1 (fr) * 2002-06-17 2003-12-19 Centre Nat Rech Scient Agent anti-resistance a l'oxaliplatine
WO2006045053A2 (fr) * 2004-10-20 2006-04-27 Hitachi Chemical Company, Ltd. Methode permettant de personnaliser l'administration de medicaments par analyse quantitative de l'arnm

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840923A1 (fr) * 2002-06-17 2003-12-19 Centre Nat Rech Scient Agent anti-resistance a l'oxaliplatine
WO2006045053A2 (fr) * 2004-10-20 2006-04-27 Hitachi Chemical Company, Ltd. Methode permettant de personnaliser l'administration de medicaments par analyse quantitative de l'arnm

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMAS A ET AL: "DRUG-INDUCED APOPTOSIS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RELATIONSHIP BETWEEN P53 GENE MUTATION AND BCL-2/BAX PROTEINS IN DRUG RESISTANCE", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 12, no. 5, 7 March 1996 (1996-03-07), pages 1055 - 1062, XP001001220, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO2007038406A1 (fr) 2007-04-05

Similar Documents

Publication Publication Date Title
US12241900B2 (en) Markers for renal disease
JP7022969B2 (ja) ＳＡＲＳ－ＣｏＶ－２感染症を診断するための方法および試薬
JP2023065484A (ja) 新規タウ種
CN103370620B (zh) 阿尔茨海默病的诊断药和诊断方法
US20090221004A1 (en) Caspase-cleavage anti-keratin antibodies for detection of apoptosis
EA034364B1 (ru) Иммуноанализ для обнаружения хромогранина а
KR101495225B1 (ko) Ast 양의 측정을 통한 간 질환 진단, 예후 또는 모니터링 키트 및 방법
WO2007038579A1 (fr) L'expression du bas permettant de prevoir la reponse au traitement d'une maladie hematologique
AU2017204520B2 (en) Markers for renal disease
JP6829689B2 (ja) 免疫試験方法および免疫試験キット
JP2009052933A (ja) プリオン病の検出方法及び診断キット
Findlater Peripherin-28 as a biomarker of ALS: A methodological study

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06815560

Country of ref document: EP

Kind code of ref document: A1